Genmab has morphed from a cash - burning operation into a profitable business especially due to the success of blood cancer drug Darzalex, on which it is paid a royalty of 12 to 20 percent on sales of the drug. (cnbc.com)
Agios lifted by milestone blood cancer drug approval. (fortune.com)
Bayer blood cancer drug nabs FDA priority review. (fortune.com)